Search

Your search keyword '"Negrini S."' showing total 1,205 results
Start Over Author "Negrini S."
1,205 results on '"Negrini S."'

4. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

Author

Hoffmann-Vold A. -M., Brunborg C., Airo P., Ananyeva L. P., Czirjak L., Guiducci S., Hachulla E., Li M., Mihai C., Riemekasten G., Sfikakis P. P., Valentini G., Kowal-Bielecka O., Allanore Y., Distler O., Vacca A., Giollo A., Balbir-Gurman A., Gheorghiu A. M., Marcoccia A., Herrick A., Radic M., Stamenkovic B., Anic B., Granel B., Ribi C., Selmi C. F., Carlos de la Puente M., de Souza Muller C., Denton C., Kayser C., Tanaseanu C. -M., Majewski D., Rimar D., Krasowska D., Veale D., Walker U., Kerzberg E., Rezus E., Zanatta E., Siegert E., De Langhe E., Oksel F., Ingegnoli F., Cantatore F. P., Szucs G., Cuomo G., Seskute G., Litinsky V., Castellvi I., Morovic-Vergles J., Sibilia J., Henes J., Solanki K., Perdan-Pirkmajer K., Herrmann K., Saketkoo L. A., Stamp L., Mouthon L., Salvador M. J., Pozzi M. R., Uprus M., Vanthuyne M., Engelhart M., Kohm M., Iudici M., Inanc M., Fathi N., Pamuk N., Garcia de la Pena Lefebv P., Carreira P. E., Bancel D. F., Moroncini L., Montecucco C., Ancuta C., Sunderkotter C., Muller-Ladner U., Rosato E., Kucharz E. J., Iannone F., Del Galdo F., Poormoghim H., Kotter I., Distler J., Cutolo M., Tikly M., Damjanov N., Hunzelmann N., Vlachoyiannopoulos P., Hasler P., Sarzi Puttini P., Wiland P., Becvar R., Yavuz S., Zdrojewski Z., Pellerito R., Foti R., Ionescu R. M., Adler S., Kahl S., Moiseev S., Stebbings S., Rednic S., Negrini S., Heitmann S., Ullman S., Agachi S., Martin T., Schmeiser T., Riccieri V., Smith V., Bernardino V., Ortiz-Santamaria V., Hsu V. M., Abdel Atty Mohamed W. A., Hoffmann-Vold, A. -M., Brunborg, C., Airo, P., Ananyeva, L. P., Czirjak, L., Guiducci, S., Hachulla, E., Li, M., Mihai, C., Riemekasten, G., Sfikakis, P. P., Valentini, G., Kowal-Bielecka, O., Allanore, Y., Distler, O., Vacca, A., Giollo, A., Balbir-Gurman, A., Gheorghiu, A. M., Marcoccia, A., Herrick, A., Radic, M., Stamenkovic, B., Anic, B., Granel, B., Ribi, C., Selmi, C. F., Carlos de la Puente, M., de Souza Muller, C., Denton, C., Kayser, C., Tanaseanu, C. -M., Majewski, D., Rimar, D., Krasowska, D., Veale, D., Walker, U., Kerzberg, E., Rezus, E., Zanatta, E., Siegert, E., De Langhe, E., Oksel, F., Ingegnoli, F., Cantatore, F. P., Szucs, G., Cuomo, G., Seskute, G., Litinsky, V., Castellvi, I., Morovic-Vergles, J., Sibilia, J., Henes, J., Solanki, K., Perdan-Pirkmajer, K., Herrmann, K., Saketkoo, L. A., Stamp, L., Mouthon, L., Salvador, M. J., Pozzi, M. R., Uprus, M., Vanthuyne, M., Engelhart, M., Kohm, M., Iudici, M., Inanc, M., Fathi, N., Pamuk, N., Garcia de la Pena Lefebv, P., Carreira, P. E., Bancel, D. F., Moroncini, L., Montecucco, C., Ancuta, C., Sunderkotter, C., Muller-Ladner, U., Rosato, E., Kucharz, E. J., Iannone, F., Del Galdo, F., Poormoghim, H., Kotter, I., Distler, J., Cutolo, M., Tikly, M., Damjanov, N., Hunzelmann, N., Vlachoyiannopoulos, P., Hasler, P., Sarzi Puttini, P., Wiland, P., Becvar, R., Yavuz, S., Zdrojewski, Z., Pellerito, R., Foti, R., Ionescu, R. M., Adler, S., Kahl, S., Moiseev, S., Stebbings, S., Rednic, S., Negrini, S., Heitmann, S., Ullman, S., Agachi, S., Martin, T., Schmeiser, T., Riccieri, V., Smith, V., Bernardino, V., Ortiz-Santamaria, V., Hsu, V. M., and Abdel Atty Mohamed, W. A.

Subjects
interstitial lung disease, Pulmonary and Respiratory Medicine, enrichment, systemic sclerosis, clinical trial, Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine
Abstract

BACKGROUND: Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have not been tested in a real-life cohort.RESEARCH QUESTION: Do enrichment strategies for progressive ILD impact efficacy, repre-sentativeness, and feasibility in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database?STUDY DESIGN AND METHODS: We applied the inclusion criteria of major recent SSc-ILD trials (Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis [focuSSced], Scleroderma Lung Study II [SLS II], and Safety and Efficacy of Nintedanib in Systemic Sclerosis [SENSCIS]) and assessed progressive ILD, which was defined as absolute change in FVC and as significant progression (FVC decline $10%). Data were compared with all patients and with patients who did not fulfill any inclusion criteria. RESULTS: In total, 2,258 patients with SSc-ILD were included: 31.2% of the patients met SENSCIS criteria; 5.8% of the patients met SLS II criteria; 1.6% of the patients met focuSSced criteria, and 67.7% (1,529) of the patients did not meet any criteria. In the first 12 + 3 months, the absolute FVC decline in all patients and in patients who fulfilled criteria from SENSCIS was -0.1%, in patients who fulfilled criteria from focuSSced was -3.7%, and in patients who fulfilled criteria from SLS II was 2.3%, with accompanying more progressors in focuSSced. The patient populations that fulfilled the different study inclusion criteria significantly differed in various clinical parameters. In the second 12-month period, SENSCIS-enriched patients had a further absolute FVC% decline as described for the total cohort. In contrast, patients who fulfilled the focuSSced and SLS II criteria showed numeric improvement of lung function. There were no significant associations of enrichment criteria and ILD progression.INTERPRETATION: The application of enrichment criteria from previous clinical trials showed enrichment for progression with variable success, which led to selected patient populations reducing feasibility of recruitment. These findings are important for future clinical trial design and interpretation of the results of published trials.CHEST 2023; 163(3):586-598

Published
2023

8. Arthralgia: a map of Cochrane evidence relevant to rehabilitation for people with post COVID-19 condition

Author

Cordani, C., Lazzarini, S.G., Del Furia, M.J., Kiekens, C., Arienti, C., and Negrini, S.

Subjects
Settore MED/34 - Medicina Fisica e Riabilitativa, Physical and rehabilitation medicine, Rehabilitation, Arthralgia, COVID-19, Pain, post-acute COVID-19 syndrome, Physical Therapy, Sports Therapy and Rehabilitation
Abstract

Rehabilitation focuses on impairments, activity limitations and participation restrictions being informed by the underlying health condition. In the current absence of direct "evidence on" rehabilitation interventions for people with post-COVID-19 condition (PCC), we can search and synthesize the indirect "evidence relevant to" coming from interventions effective on the symptoms of PCC in other health conditions. The World Health Organization (WHO) required this information to inform expert teams and provide specific recommendations in its Guidelines. With this overview of reviews with mapping we aimed to synthesize the Cochrane evidence relevant to rehabilitation for arthralgia due to PCC in a map.We searched the last five years' Cochrane Systematic Review (CSRs) using the terms "arthralgia," "joint pain," and "rehabilitation" and their synonyms in the Cochrane Library. We extracted and summarized all the available evidence using a map. We grouped the included CSRs for health conditions and interventions, indicating the effect and the quality of evidence.We found 200 CSRs published between 2016 and 2021, and included 11 in this overview. They provided data from 7 health conditions, with osteoarthritis (5 studies) being the most studied. Effective rehabilitation interventions included exercise training, transcranial magnetic stimulation, different types of electrical stimulation and Tai chi. The overall quality of evidence was mainly low to very low, and moderate in a few cases.These results provided the requested information to the WHO and served as the basis for one recommendation on treatments for arthralgia due to PCC in the current Guidelines for clinical practice. These results should be interpreted as a first step of indirect evidence able to generate helpful hypotheses for future research.

Published
2023

10. Rehabilitation and COVID-19: update of the rapid living systematic review by Cochrane Rehabilitation Field as of December 31st, 2021

Author

Negrini F., De Sire A., Andrenelli E., Lazzarini S. G., Patrini M., Ceravolo M. G., Kiekens C., Arienti C., Cote P., Cusick A., De Groote W., Gimigliano F., Heinemann A. W., Rathore F. A., Rizzi M., Verheyden G., Walshe M., Negrini S., Negrini, F., De Sire, A., Andrenelli, E., Lazzarini, S. G., Patrini, M., Ceravolo, M. G., Kiekens, C., Arienti, C., Cote, P., Cusick, A., De Groote, W., Gimigliano, F., Heinemann, A. W., Rathore, F. A., Rizzi, M., Verheyden, G., Walshe, M., and Negrini, S.

Subjects
Settore MED/34 - Medicina Fisica e Riabilitativa, SARS-CoV-2, Rehabilitation, COVID-19, Humans, Physical Therapy, Sports Therapy and Rehabilitation
Published
2022

13. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Author

Bettiol, A., Urban, M. L., Dagna, L., Cottin, V., Franceschini, F., Del Giacco, S., Schiavon, F., Neumann, T., Lopalco, G., Novikov, P., Baldini, C., Lombardi, C., Berti, A., Alberici, F., Folci, M., Negrini, S., Sinico, R. A., Quartuccio, L., Lunardi, C., Parronchi, P., Moosig, F., Espigol-Frigole, G., Schroeder, J., Kernder, A. L., Monti, S., Silvagni, E., Crimi, C., Cinetto, F., Fraticelli, P., Roccatello, D., Vacca, A., Mohammad, A. J., Hellmich, B., Samson, M., Bargagli, E., Cohen Tervaert, J. W., Ribi, C., Fiori, D., Bello, F., Fagni, F., Moroni, L., Ramirez, G. A., Nasser, M., Marvisi, C., Toniati, P., Firinu, D., Padoan, R., Egan, A., Seeliger, B., Iannone, F., Salvarani, C., Jayne, D., Prisco, D., Vaglio, A., Emmi, G., Ahmad, K., Beccalli, M., Bonnotte, B., Bortolotti, R., Cariddi, A., Caminati, M., Cid, M. C., Deidda, M., Delvino, P., Scala, G. D., Felicetti, M., Ferro, F., Furini, F., Gelain, E., Ghirelli, G., Holle, J., Losappio, L. M., Mahr, A., Malandrino, D., Marhhold, J., Mattioli, I., Moi, L., Moiseev, S., Muratore, F., Nolasco, S., Olivieri, B., Palermo, A., Regola, F., Sander, O., Scarpa, R., Sciascia, S., Silvestri, E., Susca, N., Terrier, B., Treppo, E., Trezzi, B., Uzzo, M., Vitiello, G., Yacyshyn, E., RS: MHeNs - R3 - Neuroscience, Faculteit FHML Centraal, Bettiol, A, Urban, M, Dagna, L, Cottin, V, Franceschini, F, Del Giacco, S, Schiavon, F, Neumann, T, Lopalco, G, Novikov, P, Baldini, C, Lombardi, C, Berti, A, Alberici, F, Folci, M, Negrini, S, Sinico, R, Quartuccio, L, Lunardi, C, Parronchi, P, Moosig, F, Espígol-Frigolé, G, Schroeder, J, Kernder, A, Monti, S, Silvagni, E, Crimi, C, Cinetto, F, Fraticelli, P, Roccatello, D, Vacca, A, Mohammad, A, Hellmich, B, Samson, M, Bargagli, E, Cohen Tervaert, J, Ribi, C, Fiori, D, Bello, F, Fagni, F, Moroni, L, Ramirez, G, Nasser, M, Marvisi, C, Toniati, P, Firinu, D, Padoan, R, Egan, A, Seeliger, B, Iannone, F, Salvarani, C, Jayne, D, Prisco, D, Vaglio, A, Emmi, G, Jayne, David [0000-0002-1712-0637], and Apollo - University of Cambridge Repository

Subjects
Male, Epidemiology, Birmingham Vasculitis Activity Score, law.invention, Glucocorticoid, Randomized controlled trial, Prednisone, law, Eosinophilic, Monoclonal, Immunology and Allergy, Humanized, PLACEBO, Middle Aged, egpa mepolizumab, Treatment Outcome, SAFETY, Female, ANCA-associated Vasculitis, Biologicals, Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss), Glucocorticoids, Granulomatosis with polyangiitis, ANCA-associated Vasculiti, medicine.drug, Keywords: ANCA-associated Vasculitis, Adult, medicine.medical_specialty, Immunology, Antibodies, Monoclonal, Humanized, Antibodies, Drug Administration Schedule, Eosinophilia, Granulomatosis with Polyangiitis, Humans, Retrospective Studies, Rheumatology, Internal medicine, medicine, Adverse effect, Asthma, business.industry, medicine.disease, Biological, EGPA, European EGPA Study Group, business, FOLLOW-UP, Mepolizumab
Abstract

OBJECTIVE: Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In a few recently reported studies, successful real-life experiences with the approved dose for treating severe eosinophilic asthma (100 mg every 4 weeks) were observed. We undertook this study to assess the effectiveness and safety of mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks in a large European EGPA cohort. METHODS: We included all patients with EGPA treated with mepolizumab at the recruiting centers in 2015-2020. Treatment response was evaluated from 3 months to 24 months after initiation of mepolizumab. Complete response to treatment was defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] = 0) and a prednisolone or prednisone dose (or equivalent) of ���4 mg/day. Respiratory outcomes included asthma and ear, nose, and throat (ENT) exacerbations. RESULTS: Two hundred three patients, of whom 191 received a stable dose of mepolizumab (158 received 100 mg every 4 weeks and 33 received 300 mg every 4 weeks) were included. Twenty-five patients (12.3%) had a complete response to treatment at 3 months. Complete response rates increased to 30.4% and 35.7% at 12 months and 24 months, respectively, and rates were comparable between mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks. Mepolizumab led to a significant reduction in BVAS score, prednisone dose, and eosinophil counts from 3 months to 24 months, with no significant differences observed between 100 mg every 4 weeks and 300 mg every 4 weeks. Eighty-two patients (40.4%) experienced asthma exacerbations (57 of 158 [36%] who received 100 mg every 4 weeks; 17 of 33 [52%] who received 300 mg every 4 weeks), and 31 patients (15.3%) experienced ENT exacerbations. Forty-four patients (21.7%) experienced adverse events (AEs), most of which were nonserious AEs (38 of 44). CONCLUSION: Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks is effective for the treatment of EGPA. The 2 doses should be compared in the setting of a controlled trial.

Published
2022
Full Text
View/download PDF

14. ADVANCING ACADEMIC CAPACITY IN PHYSICAL AND REHABILITATION MEDICINE TO STRENGTHEN REHABILITATION IN HEALTH SYSTEMS WORLDWIDE: A JOINT EFFORT BY THE EUROPEAN ACADEMY OF REHABILITATION MEDICINE, THE ASSOCIATION OF ACADEMIC PHYSIATRISTS, AND THE INTERNATIONAL SOCIETY OF PHYSICAL AND REHABILITATION MEDICINE

Author

Frontera W. R., Stucki G., Engkasan J. P., Francisco G. E., Gutenbrunner C., Hasnan N., Lains J., Yusof Y. M., Negrini S., Omar Z., Battistella L. R., Sowa G., Stam H., Bickenbach J., Deltombe T., Didier J. -P., Malmivaara A., Mc-Namara A., Michail X., Paysant J., Rietman H., Vanderstraeten G., Ward A. B., Celnik P., Cuccurullo S. J., Fredericson M., Kowalske K., Lee M., Morgenroth D., Moroz A., Patel C., Powell D., Raghavan P., Stein A., Visco C., Wilson R., Gimigliano F., Laffont I., Li L., Schiappacasse C., Frontera, W. R., Stucki, G., Engkasan, J. P., Francisco, G. E., Gutenbrunner, C., Hasnan, N., Lains, J., Yusof, Y. M., Negrini, S., Omar, Z., Battistella, L. R., Sowa, G., Stam, H., Bickenbach, J., Deltombe, T., Didier, J. -P., Malmivaara, A., Mc-Namara, A., Michail, X., Paysant, J., Rietman, H., Vanderstraeten, G., Ward, A. B., Celnik, P., Cuccurullo, S. J., Fredericson, M., Kowalske, K., Lee, M., Morgenroth, D., Moroz, A., Patel, C., Powell, D., Raghavan, P., Stein, A., Visco, C., Wilson, R., Gimigliano, F., Laffont, I., Li, L., Schiappacasse, C., and Rehabilitation Medicine

Subjects
Science & Technology, Rehabilitation, Physical Therapy, Sports Therapy and Rehabilitation, General Medicine, Physical and Rehabilitation Medicine, Physiatrists, Academic Capacity, Settore MED/34 - Medicina Fisica e Riabilitativa, Medicine, Humans, Life Sciences & Biomedicine, Physical Examination, Sport Sciences
Abstract

ispartof: AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION vol:101 issue:9 pages:897-904 ispartof: location:United States status: published

Published
2022

15. The Individual Rehabilitation Project as the core of person-centered rehabilitation: the Physical and Rehabilitation Medicine Section and Board of the European Union of Medical Specialists Framework for Rehabilitation in Europe

Author

Zampolini, M., Selb, M., Boldrini, P., Branco, C. A., Golyk, V., Hu, X., Kiekens, C., Negrini, S., Nulle, A., Oral, A., Sgantzos, M., Shmonin, A., Treger, I., Stucki, G., and Rehabilitation Medicine

Subjects
Patient-centered care, Rehabilitation, Physical Therapy, Sports Therapy and Rehabilitation, Physical and Rehabilitation Medicine, Rehabilitation Centers, Article, Europe, Settore MED/34 - Medicina Fisica e Riabilitativa, disability and health, Humans, International classification of functioning, disability and health, Disabled Persons, European Union, International classification of functioning
Abstract

To facilitate the interaction between the health professional and the patient, a framework to guide the rehabilitation process is needed. This framework would encompass three interwoven aspects: the rehabilitation management plan, Individual Rehabilitation Project (IRP), and rehabilitation cycle(s). All three framework aspects focus on the patient and on the aim of rehabilitation, i.e. to optimize a person's functioning across the continuum of care. An IRP is a multi-element, person-centered rehabilitation management scheme, in which rehabilitation is generally provided by a multiprofessional team under the leadership of a physical and rehabilitation medicine (PRM) physician, working in an interdisciplinary manner and together with the patient (or proxy). A reference system for operationalizing functioning and standardizing the process is the International Classification of Functioning, Disability and Health (ICF) - for assessing functioning needs, defining rehabilitation goals and outcomes. The objective of this paper is to present the IRP as a framework for rehabilitation in Europe (EUR-IRP). The specific aims are: 1) to introduce the IRP; and 2) to describe the framework components, elements and variables of the IRP. Demonstration projects (case studies) using the EUR-IRP will be conducted. The present paper presents the efforts to date for developing the EUR-IRP, a key part of the action plan of the PRM Section and Board of the European Union of Medical Specialists to implement the ICF systemwide across the care continuum. This paper serves as another step to bring together practice, science and governance in calling for contribution from rehabilitation clinicians and researchers and professional societies in PRM and beyond.

Published
2022

18. Covid-19 and the role of smoking: The protocol of the multicentric prospective study COSMO-IT (covid19 and smoking in italy)

Author

Cattaruzza, M, Gorini, G, Bosetti, C, Boffi, R, Lugo, A, Veronese, C, Carreras, G, Santucci, C, Stival, C, Pacifici, R, Zaga, V, Gallus, S, Giulietti, F, Sarzani, R, Spannella, F, Del Donno, M, Tartaglione, S, Marrazzo, G, Pelaia, G, D'Agosto, V, Berti, A, Voller, F, Cardellicchio, S, Cresci, C, Foschino Barbaro, M, De Palma, R, Negrini, S, Sicbaldi, V, Serafini, A, Bisconti, M, Refolo, L, Landoni, G, Rovere, P, Veronesi, G, Faverio, P, Garavello, W, Pesci, A, Giacobbe, R, Martucci, P, Parrella, R, Scarano, F, Aiello, M, Chetta, A, Franco, C, Mangia, A, Carrozzi, L, Maggi Monzani, F, Pistelli, F, Russo, P, Sanna, A, Barreca, F, Conti, V, Rossi, E, Ruli, M, Ruli, S, Varzaneh, S, Principe, R, Guerrini, S, Sebastiani, A, Galluccio, G, Pezzuto, A, Ricci, A, Casali, E, Mastroianni, C, Pirina, P, Polo, F, Beatrice, F, Romagnoli, M, Baraldo, M, Cojutti, P, Graziano, E, Pecori, D, Tascini, C, Tinghino, B, Cattaruzza M. S., Gorini G., Bosetti C., Boffi R., Lugo A., Veronese C., Carreras G., Santucci C., Stival C., Pacifici R., Zaga V., Gallus S., Giulietti F., Sarzani R., Spannella F., Del Donno M., Tartaglione S., Marrazzo G., Pelaia G., D'agosto V., Berti A., Voller F., Cardellicchio S., Cresci C., Foschino Barbaro M. P., De Palma R., Negrini S., Sicbaldi V., Serafini A., Bisconti M., Refolo L., Landoni G., Rovere P., Veronesi G., Faverio P., Garavello W., Pesci A., Giacobbe R., Martucci P., Parrella R., Scarano F., Aiello M., Chetta A., Franco C., Mangia A., Carrozzi L., Maggi Monzani F. F., Pistelli F., Russo P., Sanna A., Barreca F. M., Conti V., Rossi E., Ruli M., Ruli S., Varzaneh S. E., Principe R., Guerrini S., Sebastiani A., Galluccio G., Pezzuto A., Ricci A., Casali E., Mastroianni C., Pirina P., Polo F., Beatrice F., Romagnoli M., Baraldo M., Cojutti P. G., Graziano E., Pecori D., Tascini C., Tinghino B., Cattaruzza, M, Gorini, G, Bosetti, C, Boffi, R, Lugo, A, Veronese, C, Carreras, G, Santucci, C, Stival, C, Pacifici, R, Zaga, V, Gallus, S, Giulietti, F, Sarzani, R, Spannella, F, Del Donno, M, Tartaglione, S, Marrazzo, G, Pelaia, G, D'Agosto, V, Berti, A, Voller, F, Cardellicchio, S, Cresci, C, Foschino Barbaro, M, De Palma, R, Negrini, S, Sicbaldi, V, Serafini, A, Bisconti, M, Refolo, L, Landoni, G, Rovere, P, Veronesi, G, Faverio, P, Garavello, W, Pesci, A, Giacobbe, R, Martucci, P, Parrella, R, Scarano, F, Aiello, M, Chetta, A, Franco, C, Mangia, A, Carrozzi, L, Maggi Monzani, F, Pistelli, F, Russo, P, Sanna, A, Barreca, F, Conti, V, Rossi, E, Ruli, M, Ruli, S, Varzaneh, S, Principe, R, Guerrini, S, Sebastiani, A, Galluccio, G, Pezzuto, A, Ricci, A, Casali, E, Mastroianni, C, Pirina, P, Polo, F, Beatrice, F, Romagnoli, M, Baraldo, M, Cojutti, P, Graziano, E, Pecori, D, Tascini, C, Tinghino, B, Cattaruzza M. S., Gorini G., Bosetti C., Boffi R., Lugo A., Veronese C., Carreras G., Santucci C., Stival C., Pacifici R., Zaga V., Gallus S., Giulietti F., Sarzani R., Spannella F., Del Donno M., Tartaglione S., Marrazzo G., Pelaia G., D'agosto V., Berti A., Voller F., Cardellicchio S., Cresci C., Foschino Barbaro M. P., De Palma R., Negrini S., Sicbaldi V., Serafini A., Bisconti M., Refolo L., Landoni G., Rovere P., Veronesi G., Faverio P., Garavello W., Pesci A., Giacobbe R., Martucci P., Parrella R., Scarano F., Aiello M., Chetta A., Franco C., Mangia A., Carrozzi L., Maggi Monzani F. F., Pistelli F., Russo P., Sanna A., Barreca F. M., Conti V., Rossi E., Ruli M., Ruli S., Varzaneh S. E., Principe R., Guerrini S., Sebastiani A., Galluccio G., Pezzuto A., Ricci A., Casali E., Mastroianni C., Pirina P., Polo F., Beatrice F., Romagnoli M., Baraldo M., Cojutti P. G., Graziano E., Pecori D., Tascini C., and Tinghino B.

Abstract

The emergency caused by Covid-19 pandemic raised interest in studying lifestyles and comorbidities as important determinants of poor Covid-19 prognosis. Data on tobacco smoking, alcohol consumption and obesity are still limited, while no data are available on the role of e-cigarettes and heated tobacco products (HTP). To clarify the role of tobacco smoking and other lifestyle habits on COVID-19 severity and progression, we designed a longitudinal observational study titled COvid19 and SMOking in ITaly (COSMO-IT). About 30 Italian hospitals in North, Centre and South of Italy joined the study. Its main aims are: 1) to quantify the role of tobacco smoking and smoking cessation on the severity and progression of COVID-19 in hospitalized patients; 2) to compare smoking prevalence and severity of the disease in relation to smoking in hospitalized COVID-19 patients versus patients treated at home; 3) to quantify the association between other lifestyle factors, such as e-cigarette and HTP use, alcohol and obesity and the risk of unfavourable COVID-19 outcomes. Socio-demographic, lifestyle and medical history information will be gathered for around 3000 hospitalized and 700-1000 home-isolated, laboratory-confirmed, COVID-19 patients. Given the current absence of a vaccine against SARS-COV-2 and the lack of a specific treatment for COVID-19, prevention strategies are of extreme importance. This project, designed to highly contribute to the international scientific debate on the role of avoidable lifestyle habits on COVID-19 severity, will provide valuable epidemiological data in order to support important recommendations to prevent COVID-19 incidence, progression and mortality.

Published
2020

19. Rehabilitation and COVID-19: update of the rapid living systematic review by Cochrane Rehabilitation Field as of February 28, 2021

Author

Andrenelli E., Negrini F., De Sire A., Patrini M., Lazzarini S. G., Ceravolo M. G., Kiekens C., Arienti C., Cote P., Cusick A., Gimigliano F., Heinemann A. W., Mills J. -A., Rathore F., Rizzi M., Verheyden G., Walshe M., Negrini S., Andrenelli, E., Negrini, F., De Sire, A., Patrini, M., Lazzarini, S. G., Ceravolo, M. G., Kiekens, C., Arienti, C., Cote, P., Cusick, A., Gimigliano, F., Heinemann, A. W., Mills, J. -A., Rathore, F., Rizzi, M., Verheyden, G., Walshe, M., and Negrini, S.

Subjects
SARS-CoV-2, Rehabilitation, COVID-19, Humans, Physical Therapy, Sports Therapy and Rehabilitation, Pandemics, Systematic Reviews as Topic
Published
2021

20. Evidence for charge-based mimicry in anti dsDNA antibody generation

Author

Bruschi, M, Angeletti, A, Kajana, X, Moroni, G, Sinico, R, Fredi, M, Vaglio, A, Cavagna, L, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Negrini, S, Bui, F, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, Fenaroli, P, Pisani, I, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Verrina, E, Franceschini, F, Ravelli, A, Prunotto, M, Meroni, P, Ghiggeri, G, Bruschi, Maurizio, Angeletti, Andrea, Kajana, Xhuliana, Moroni, Gabriella, Sinico, Renato Alberto, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe Alvise, Esposito, Pasquale, Negrini, Simone, Bui, Federica, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisani, Isabella, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Verrina, Enrico, Franceschini, Franco, Ravelli, Angelo, Prunotto, Marco, Meroni, Pier Luigi, Ghiggeri, Gian Marco, Bruschi, M, Angeletti, A, Kajana, X, Moroni, G, Sinico, R, Fredi, M, Vaglio, A, Cavagna, L, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Negrini, S, Bui, F, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, Fenaroli, P, Pisani, I, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Verrina, E, Franceschini, F, Ravelli, A, Prunotto, M, Meroni, P, Ghiggeri, G, Bruschi, Maurizio, Angeletti, Andrea, Kajana, Xhuliana, Moroni, Gabriella, Sinico, Renato Alberto, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe Alvise, Esposito, Pasquale, Negrini, Simone, Bui, Federica, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisani, Isabella, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Verrina, Enrico, Franceschini, Franco, Ravelli, Angelo, Prunotto, Marco, Meroni, Pier Luigi, and Ghiggeri, Gian Marco

Abstract

Mechanisms for the generation of anti-dsDNA autoantibodies are still not completely elucidated. One theory states that dsDNA interacts for mimicry with antibodies raised versus other antigens but molecular features for mimicry are unknown. Here we show that, at physiological acid-base balance, anti-Annexin A1 binds IgG2 dsDNA in a competitive and dose-dependent way with Annexin A1 and that the competition between the two molecules is null at pH 9. On the other hand, these findings also show that dsDNA and Annexin A1 interact with their respective antibodies on a strictly pH-dependent basis: in both cases, the binding was minimal at pH 4 and maximal at pH9-10. The anionic charge of dsDNA is mainly conferred by the numerous phosphatidic residues. The epitope binding site of Annexin A1 for anti-Annexin A1 IgG2 was here characterized as a string of 34 amino acids at the NH2 terminus, 10 of which are anionic. Circulating levels of anti-dsDNA and anti-Annexin A1 IgG2 antibodies were strongly correlated in patients with systemic lupus erythematosus (n 496) and lupus nephritis (n 425) stratified for age, sex, etc. These results show that dsDNA competes with Annexin A1 for the binding with anti-Annexin A1 IgG2 on a dose and charged mediated base, being able to display an inhibition up to 75%. This study provides the first demonstration that dsDNA may interact with antibodies raised versus other anionic molecules (anti-Annexin A1 IgG2) because of charge mimicry and this interaction may contribute to anti-dsDNA antibodies generation.

Published
2022

21. Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study

Author

Bettiol, A, Urban, M, Dagna, L, Cottin, V, Franceschini, F, Del Giacco, S, Schiavon, F, Neumann, T, Lopalco, G, Novikov, P, Baldini, C, Lombardi, C, Berti, A, Alberici, F, Folci, M, Negrini, S, Sinico, R, Quartuccio, L, Lunardi, C, Parronchi, P, Moosig, F, Espígol-Frigolé, G, Schroeder, J, Kernder, A, Monti, S, Silvagni, E, Crimi, C, Cinetto, F, Fraticelli, P, Roccatello, D, Vacca, A, Mohammad, A, Hellmich, B, Samson, M, Bargagli, E, Cohen Tervaert, J, Ribi, C, Fiori, D, Bello, F, Fagni, F, Moroni, L, Ramirez, G, Nasser, M, Marvisi, C, Toniati, P, Firinu, D, Padoan, R, Egan, A, Seeliger, B, Iannone, F, Salvarani, C, Jayne, D, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Urban, Maria Letizia, Dagna, Lorenzo, Cottin, Vincent, Franceschini, Franco, Del Giacco, Stefano, Schiavon, Franco, Neumann, Thomas, Lopalco, Giuseppe, Novikov, Pavel, Baldini, Chiara, Lombardi, Carlo, Berti, Alvise, Alberici, Federico, Folci, Marco, Negrini, Simone, Sinico, Renato Alberto, Quartuccio, Luca, Lunardi, Claudio, Parronchi, Paola, Moosig, Frank, Espígol-Frigolé, Georgina, Schroeder, Jan, Kernder, Anna Luise, Monti, Sara, Silvagni, Ettore, Crimi, Claudia, Cinetto, Francesco, Fraticelli, Paolo, Roccatello, Dario, Vacca, Angelo, Mohammad, Aladdin J, Hellmich, Bernhard, Samson, Maxime, Bargagli, Elena, Cohen Tervaert, Jan Willem, Ribi, Camillo, Fiori, Davide, Bello, Federica, Fagni, Filippo, Moroni, Luca, Ramirez, Giuseppe Alvise, Nasser, Mouhamad, Marvisi, Chiara, Toniati, Paola, Firinu, Davide, Padoan, Roberto, Egan, Allyson, Seeliger, Benjamin, Iannone, Florenzo, Salvarani, Carlo, Jayne, David, Prisco, Domenico, Vaglio, Augusto, Emmi, Giacomo, Bettiol, A, Urban, M, Dagna, L, Cottin, V, Franceschini, F, Del Giacco, S, Schiavon, F, Neumann, T, Lopalco, G, Novikov, P, Baldini, C, Lombardi, C, Berti, A, Alberici, F, Folci, M, Negrini, S, Sinico, R, Quartuccio, L, Lunardi, C, Parronchi, P, Moosig, F, Espígol-Frigolé, G, Schroeder, J, Kernder, A, Monti, S, Silvagni, E, Crimi, C, Cinetto, F, Fraticelli, P, Roccatello, D, Vacca, A, Mohammad, A, Hellmich, B, Samson, M, Bargagli, E, Cohen Tervaert, J, Ribi, C, Fiori, D, Bello, F, Fagni, F, Moroni, L, Ramirez, G, Nasser, M, Marvisi, C, Toniati, P, Firinu, D, Padoan, R, Egan, A, Seeliger, B, Iannone, F, Salvarani, C, Jayne, D, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Urban, Maria Letizia, Dagna, Lorenzo, Cottin, Vincent, Franceschini, Franco, Del Giacco, Stefano, Schiavon, Franco, Neumann, Thomas, Lopalco, Giuseppe, Novikov, Pavel, Baldini, Chiara, Lombardi, Carlo, Berti, Alvise, Alberici, Federico, Folci, Marco, Negrini, Simone, Sinico, Renato Alberto, Quartuccio, Luca, Lunardi, Claudio, Parronchi, Paola, Moosig, Frank, Espígol-Frigolé, Georgina, Schroeder, Jan, Kernder, Anna Luise, Monti, Sara, Silvagni, Ettore, Crimi, Claudia, Cinetto, Francesco, Fraticelli, Paolo, Roccatello, Dario, Vacca, Angelo, Mohammad, Aladdin J, Hellmich, Bernhard, Samson, Maxime, Bargagli, Elena, Cohen Tervaert, Jan Willem, Ribi, Camillo, Fiori, Davide, Bello, Federica, Fagni, Filippo, Moroni, Luca, Ramirez, Giuseppe Alvise, Nasser, Mouhamad, Marvisi, Chiara, Toniati, Paola, Firinu, Davide, Padoan, Roberto, Egan, Allyson, Seeliger, Benjamin, Iannone, Florenzo, Salvarani, Carlo, Jayne, David, Prisco, Domenico, Vaglio, Augusto, and Emmi, Giacomo

Abstract

Objective: Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort. Methods: We included all EGPA patients treated with mepolizumab at the recruiting centres in 2015-2020. Treatment response was evaluated from month 3 through 24 (T3-T24) after mepolizumab starting. Complete response (CR) was defined as no disease activity (Birmingham Vasculitis Activity Score, BVAS=0) and a prednisone dose ≤4mg/day. Respiratory outcomes included asthma and ear-nose-throat (ENT) exacerbations. Results: We included 203 patients, of whom 191 at stable dosage (158 mepolizumab 100mg/4 weeks, 33 300mg/4 weeks). At T3, 25 patients (12.3%) had a CR. CR rates increased to 30.4% and 35.7% at T12 and T24 and were comparable between mepolizumab 100 and 300mg/4 weeks. Mepolizumab led to a significant reduction in BVAS, prednisone dose, eosinophil counts from T3 through T24, with no significant differences between 100 and 300 mg/4weeks. Eighty-two patients (40.4%) experienced asthma exacerbations [57/158 (36%) on 100mg/4 weeks; 17/33 (52%) on 300mg/4 weeks]. Thirty-one (15.3%) experienced ENT exacerbations. Forty-four patients (21.7%) experienced adverse events, most being non-serious (38/44). Conclusion: Mepolizumab both at 100 and 300mg/4 weeks is effective for EGPA. The two dosages should be compared in the setting of a controlled trial.

Published
2022

22. New York Heart Association class and pulmonary artery pressure as prognostic factors of interstitial lung disease survival.

Author

CARBONE, R. G., MONSELISE, A., FILIBERTI, R. A., PENNA, D., NEGRINI, S., and PUPPO, F.

Abstract

OBJECTIVE: The aim of this study was to evaluate New York Heart Association (NYHA) class and systolic pulmonary artery pressure (sPAP) as survival predictors in major interstitial lung diseases (ILD) including idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and hypersensitivity pneumonitis (HP) and in other ILD like granulomatosis with polyangiitis (GPA). PATIENTS AND METHODS: We analyzed survival, NYHA class, sPAP, and Octreoscan uptake index (UI) in 104 ILD patients (59 IPF, 19 NSIP, 10 HP and 16 GPA; median age 60.5 years) all referred to a single centre. RESULTS: Median survival was 68 months, with 1- and 2-year survival of 91% and 78%, respectively. Survival was lower among IPF and NSIP vs. HP and GPA patients (p=0.01). NYHA class 3-4 was more frequent among IPF (76.3%) vs. NSIP patients (31.6%; p<0.001). HP and GPA had NYHA class 1-2. NYHA class was negatively associated with survival (class 1=90.3 months vs. class 3=18.3 months and class 4=5.1 months; p=0.001). sPAP was >55 mmHg in 76.3% of patients with IPF and 35-55 mmHg in 63.2% of patients with NSIP. Patients with HP and GPA had sPAP < 55 mmHg. Among patients with IPF, NYHA and sPAP were negatively associated with survival (p<0.01) both showed a parallel trend. High-resolution computed tomography and survival were worse among IPF and NSIP vs. HP and GPA patients (p<0.001). Octreoscan UI was <10, 10-12, and >12 in IPF, NSIP, HP and GPA, respectively. Octreoscan UI was negatively associated with survival (p=0.002). CONCLUSIONS: NYHA class and sPAP are comparable ILD survival predictors. NYHA class is correlated with worse prognosis for IPF and NSIP vs. HP and GPA patients. [ABSTRACT FROM AUTHOR]

Published
2023

23. POS0246 SEQUENTIAL RITUXIMAB AND MEPOLIZUMAB IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Author

Bettiol, A., primary, Urban, M. L., additional, Bello, F., additional, Fiori, D., additional, Mattioli, I., additional, Lopalco, G., additional, Iannone, F., additional, Egan, A., additional, Moroni, L., additional, Dagna, L., additional, Caminati, M., additional, Negrini, S., additional, Cameli, P., additional, Folci, M., additional, Toniati, P., additional, Padoan, R., additional, Flossmann, O., additional, Solans-Laqué, R., additional, Losappio, L., additional, Schroeder, J., additional, André, M., additional, Moi, L., additional, Parronchi, P., additional, Conti, F., additional, Sciascia, S., additional, Jayne, D., additional, Vaglio, A., additional, and Emmi, G., additional

Published
2022
Full Text
View/download PDF

24. AB0441 PREDICTORS OF CLASI RESPONSE OVER TIME IN A MULTICENTRIC REAL LIFE COHORT OF SLE PATIENTS TREATED WITH BELIMUMAB

Author

Gatto, M., primary, Depascale, R., additional, Tincani, A., additional, Emmi, G., additional, Scarpato, S., additional, Conti, F., additional, Govoni, M., additional, Mosca, M., additional, Gerosa, M., additional, Bozzolo, E., additional, Canti, V., additional, Gabrielli, A., additional, Gremese, E., additional, De Vita, S., additional, Ciccia, F., additional, Salvarani, C., additional, Rossini, M., additional, Faggioli, P., additional, Laria, A., additional, De Paulis, A., additional, Gerli, R., additional, Brunetta, E., additional, Mathieu, A., additional, Selmi, C., additional, De Angelis, R., additional, Negrini, S., additional, Zen, M., additional, Doria, A., additional, and Iaccarino, L., additional

Published
2022
Full Text
View/download PDF

25. Trust/untrust is not the same as true/false. lessons learned and ethical questions on the application of untrustworthiness scales to judge individuals

Author

Negrini, S., Ceravolo, M. G., Ferriero, G., Frischknecht, R., Karppinen, J., Küçükdeveci, A. A., and Zampolini, M.

Subjects
Settore MED/34 - Medicina Fisica e Riabilitativa, Ethics, Rehabilitation, Serial publications, Physical Therapy, Sports Therapy and Rehabilitation, Trust
Abstract

This special paper reflects on trustworthiness and its implications for scientific medical journals and all the communities they serve: health professionals, policymakers, the public, and a specific discipline, in our case, Physical and Rehabilitation Medicine. We start from a recent episode: a paper claimed the untrustworthiness of two randomised controlled trials (RCTs) published in the European Journal of Physical and Rehabilitation Medicine based on a newly developed trustworthiness scale, used until now only in systematic reviews. This likely represents the first case of applying such a scale focusing on a single leading author. Developing a proper answer to this case led us to present some insights from the perspective of a Journal editor. We discuss the impact of false research results, why trust is needed in science and medicine, the difference between untrust and false results, the problems in judging trustworthiness, the unfortunately weak capacity of the peer review system in preventing these issues, the problems of "post-hoc" judgements and the emerging ethical issues. We conclude with some suggestions for the future based on prevention at the system level.

Published
2022

27. Rehabilitation and COVID-19: A rapid living systematic review by cochrane rehabilitation field updated as of December 31st, 2020 and synthesis of the scientific literature of 2020

Author

de Sire A., Andrenelli E., Negrini F., Patrini M., Lazzarini S. G., Ceravolo M. G., Kiekens C., Arienti C., Cote P., Cusick A., Gimigliano F., Heinemann A., Mills J. -A., Rathore F., Rizzi M., Verheyden G., Walshe M., Negrini S., de Sire, A., Andrenelli, E., Negrini, F., Patrini, M., Lazzarini, S. G., Ceravolo, M. G., Kiekens, C., Arienti, C., Cote, P., Cusick, A., Gimigliano, F., Heinemann, A., Mills, J. -A., Rathore, F., Rizzi, M., Verheyden, G., Walshe, M., and Negrini, S.

Subjects
030506 rehabilitation, medicine.medical_specialty, medicine.medical_treatment, Coronaviru, Scopus, MEDLINE, Physical Therapy, Sports Therapy and Rehabilitation, Scientific literature, Disease, CINAHL, Coronavirus, COVID-19, Physical, Rehabilitation, Rehabilitation Medicine, SARS-CoV-2, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Pandemics, business.industry, Evidence-based medicine, Natural history, Physical therapy, Periodicals as Topic, 0305 other medical science, business, 030217 neurology & neurosurgery
Abstract

Introduction COVID-19 infection significantly increased mortality risk and the burden of disability in most survivors, regardless of symptom severity at onset. The rehabilitation needs of people infected are receiving growing attention, as evidenced by the increasing number of publications, including those addressing the chronic consequences of infection. This rapid living systematic review reports the evidence published in November and December 2020 and summarises the entire body of literature on rehabilitation in COVID-19 patients published in 2020. Evidence acquisition This update was performed using the methodology reported by the second edition conducted by Cochrane Rehabilitation REH-COVER Action. We searched PubMed, Embase, CINAHL, Scopus, Web of Science, and Pedro databases. Papers related to COVID-19 and rehabilitation were retrieved and summarised descriptively. Evidence synthesis The search retrieved 4441 studies. After the removal of duplicates and the screening for title and abstract, we retained 105 studies. Of these, we included 54 in the qualitative synthesis of this update. According to OCEBM 2011 levels of evidence table, most studies (64.8%) fall within the category of level 4 evidence. Up to 40.7% of papers included COVID-19 patients in the postacute phase. In 2020, our rapid living systematic review included 230 studies; most of these (73.9%) were level 4 studies, 25.7% were level 3, and only one study was level 2. The evidence level improved over time. While most studies (44.8%) included patients with acute COVID-19, we observed a gradual increase in the number of reports about chronic symptoms and the long-term consequences of the infection. Conclusions The update of the rapid living systematic review by Cochrane Rehabilitation Field demonstrates an increase in the level of evidence of studies addressing the rehabilitation needs associated with COVID-19 infection. Although most studies are still case reports/series, there is a trend towards conducting prospective investigations of the early natural history of the disease (first months post onset). High-quality-level studies on the efficacy of rehabilitation, and long-term monitoring of the disease and its sequelae are yet to emerge.

Published
2021

30. Die Definition von Rehabilitation – eine internationale vergleichende Analyse

Author

Meyer, T, Kiekens, C, Selb, M, Posthumus, E, and Negrini, S

Subjects
ddc: 610, Medicine and health
Abstract

Hintergrund und Stand (inter)nationaler Forschung: Rehabilitative Versorgungsforschung und Knowledge Translation im Feld der Rehabilitation bedarf einer geteilten, gemeinsamen Definition des Gegenstandsbereichs der Rehabilitation. Im Rahmen von Cochrane Rehabilitation wird gegenwärtig eine solche [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2021
Full Text
View/download PDF

32. Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

Author

Bettiol, A., Sinico, R. A., Schiavon, F., Monti, S., Bozzolo, E. P., Franceschini, F., Govoni, M., Lunardi, C., Guida, G., Lopalco, G., Paolazzi, G., Vacca, A., Gregorini, G., Leccese, P., Piga, M., Conti, F., Fraticelli, P., Quartuccio, L., Alberici, F., Salvarani, C., Bettio, S., Negrini, S., Selmi, C., Sciascia, S., Moroni, G., Colla, L., Manno, C., Urban, M. L., Vannacci, A., Pozzi, M. R., Fabbrini, P., Polti, S., Felicetti, M., Marchi, M. R., Padoan, R., Delvino, P., Caporali, R., Montecucco, C., Dagna, L., Cariddi, A., Toniati, P., Tamanini, S., Furini, F., Bortoluzzi, A., Tinazzi, E., Delfino, L., Badiu, I., Rolla, G., Venerito, V., Iannone, F., Berti, A., Bortolotti, R., Racanelli, V., Jeannin, G., Padula, A., Cauli, A., Priori, R., Gabrielli, A., Bond, M., Tedesco, M., Pazzola, G., Tomietto, P., Pellecchio, M., Marvisi, C., Maritati, F., Palmisano, A., Dejaco, C., Willeit, J., Kiechl, S., Olivotto, I., Willeit, P., Prisco, D., Vaglio, A., Emmi, G., Bargagli, E., Becatti, M., Beccalli, M., Bello, F., Bozzao, F., Canti, V., Cassia, M. A., Cassone, G., Catanoso, M., Chieco-Bianchi, F., Clari, R., Coladonato, L., De Santis, M., Di Scala, G., Fagni, F., Fenaroli, P., Fiorillo, C., Floris, A., Fornaro, M., Galli, E., Generali, E., Giliberti, M., Lascaro, N., Leccese, I., Mattioli, I., Olivieri, B., Osti, N., Peyronel, F., Radin, M., Righetti, G., Salvati, S., Silvestri, E., Susca, N., Tamburini, C., Taurisano, G., Trezzi, B., Trivioli, G., Bettiol, A, Sinico, R, Schiavon, F, Monti, S, Bozzolo, E, Franceschini, F, Govoni, M, Lunardi, C, Guida, G, Lopalco, G, Paolazzi, G, Vacca, A, Gregorini, G, Leccese, P, Piga, M, Conti, F, Fraticelli, P, Quartuccio, L, Alberici, F, Salvarani, C, Bettio, S, Negrini, S, Selmi, C, Sciascia, S, Moroni, G, Colla, L, Manno, C, Urban, M, Vannacci, A, Pozzi, M, Fabbrini, P, Polti, S, Felicetti, M, Marchi, M, Padoan, R, Delvino, P, Caporali, R, Montecucco, C, Dagna, L, Cariddi, A, Toniati, P, Tamanini, S, Furini, F, Bortoluzzi, A, Tinazzi, E, Delfino, L, Badiu, I, Rolla, G, Venerito, V, Iannone, F, Berti, A, Bortolotti, R, Racanelli, V, Jeannin, G, Padula, A, Cauli, A, Priori, R, Gabrielli, A, Bond, M, Tedesco, M, Pazzola, G, Tomietto, P, Pellecchio, M, Marvisi, C, Maritati, F, Palmisano, A, Dejaco, C, Willeit, J, Kiechl, S, Olivotto, I, Willeit, P, Prisco, D, Vaglio, A, and Emmi, G

Subjects
Pulmonary and Respiratory Medicine, Burden of disease, Humans, Churg-Strauss Syndrome, Granulomatosis with Polyangiitis, Venous Thromboembolism, Venous Thrombosis, Churg-strauss syndrome, Criminology, NO, 03 medical and health sciences, 0302 clinical medicine, Medicine, 030212 general & internal medicine, Vascular inflammation, business.industry, Conflict of interest, Cytoplasmic antibody, medicine.disease, 030228 respiratory system, Wegener granulomatosis, arterial and venous thromboembolic events, Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome), Organ involvement, business, Production team
Abstract

Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss syndrome) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) characterised by respiratory manifestations and systemic organ involvement [1]. Particularly, cardiac manifestations occur in 40–60% of patients, representing the leading cause of mortality [2]. Recent reports suggest that venous thromboembolic events might also represent a consistent burden of disease [3, 4], as already known for the other AAVs [5–7], possibly due to eosinophil-mediated vascular inflammation [5]. Nevertheless, the occurrence of arterial and venous thrombotic events (AVTE) has never been systematically explored in EGPA. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Alessandra Bettiol Conflict of interest: Renato Alberto Sinico Conflict of interest: Franco Schiavon Conflict of interest: Sara Monti Conflict of interest: Enrica Paola Bozzolo Conflict of interest: Franco Franceschini Conflict of interest: Marcello Govoni Conflict of interest: Claudio Lunardi Conflict of interest: Giuseppe Guida Conflict of interest: Giuseppe Lopalco Conflict of interest: Giuseppe Paolazzi Conflict of interest: Angelo Vacca Conflict of interest: Gina Gregorini Conflict of interest: Pietro Leccese Conflict of interest: Matteo Piga Conflict of interest: Fabrizio Conti Conflict of interest: Paolo Fraticelli Conflict of interest: Luca Quartuccio Conflict of interest: Federico Alberici Conflict of interest: Carlo Salvarani Conflict of interest: Silvano Bettio Conflict of interest: Simone Negrini Conflict of interest: Carlo Selmi Conflict of interest: Savino Sciascia Conflict of interest: Gabriella Moroni Conflict of interest: Loredana Colla Conflict of interest: Carlo Manno Conflict of interest: Maria Letizia Urban Conflict of interest: Alfredo Vannacci Conflict of interest: Maria Rosa Pozzi Conflict of interest: Paolo Fabbrini Conflict of interest: Stefano Polti Conflict of interest: Mara Felicetti Conflict of interest: Maria Rita Marchi Conflict of interest: Roberto Padoan Conflict of interest: Paolo Delvino Conflict of interest: Roberto Caporali Conflict of interest: Carlomaurizio Montecucco Conflict of interest: Lorenzo Dagna Conflict of interest: Adriana Cariddi Conflict of interest: Paola Toniati Conflict of interest: Dr. Tamanini reports other from Glaxo Smith Kline, outside the submitted work. Conflict of interest: Federica Furini Conflict of interest: Alessandra Bortoluzzi Conflict of interest: Elisa Tinazzi Conflict of interest: Lorenzo Delfino Conflict of interest: Iuliana Badiu Conflict of interest: Giovanni Rolla Conflict of interest: Vincenzo Venerito Conflict of interest: Florenzo Iannone Conflict of interest: Alvise Berti Conflict of interest: Roberto Bortolotti Conflict of interest: Vito Racanelli Conflict of interest: Guido Jeannin Conflict of interest: Angela Padula Conflict of interest: Alberto Cauli Conflict of interest: Roberta Priori Conflict of interest: Armando Gabrielli Conflict of interest: Milena Bond Conflict of interest: Martina Tedesco Conflict of interest: Giulia Pazzola Conflict of interest: Paola Tomietto Conflict of interest: Marco Pellecchio Conflict of interest: Chiara Marvisi Conflict of interest: Federica Maritati Conflict of interest: Alessandra Palmisano Conflict of interest: Christian Dejaco Conflict of interest: Johann Willeit Conflict of interest: Stefan Kiechl Conflict of interest: Iacopo Olivotto Conflict of interest: Peter Willeit Conflict of interest: Domenico Prisco Conflict of interest: Augusto Vaglio Conflict of interest: Giacomo Emmi

Published
2020

33. [Gimigliano F, Moretti A, Lazzarini SG, Arienti C, Ceravolo MG, Kiekens C, Negrini S]. [The Cochrane Rehabilitation Ebook Project: a knowledge translation initiative]. In: Advances in Evidence Synthesis: special issue. Cochrane Database of Systematic Reviews 2020;(9 Suppl 1):[99] https://doi.org/10.1002/14651858.CD202001

Author

Gimigliano F, Moretti A, Lazzarini SG, Arienti C, Ceravolo MG, Kiekens C, Negrini S, Gimigliano, F, Moretti, A, Lazzarini, Sg, Arienti, C, Ceravolo, Mg, Kiekens, C, and Negrini, S

Abstract

Background: Cochrane Rehabilitation (CR) is working on the production of an Ebook to systematically present all the relevant evidence of rehabilitation interest included in the Cochrane Systematic Reviews (CSRs). In line with the Cochrane Knowledge Translation (KT) strategy, the Ebook aims to fill the knowledge practice gap addressing four different audiences producing one different summary for each of them, structured to meet the needs of the different end-users according to their different knowledge skills, and outcomes of interest: clinicians, medical and health professional students, policy decision-makers and rehabilitation health care managers, patients and caregivers (consumers). Objectives: To present the CR Ebook project. Methods: After identifying all the CSRs relevant to rehabilitation, residents from two Italian universities have been involved and instructed on how to write the different summaries, using a structured template, based on the Cochrane’s Dissemination checklist, and following the Cochrane Norway language guidelines. Two Physical and Rehabilitation Medicine (PRM) physicians (AM, MGC) revised them, a second revision was provided by a member of CR and a third by at least two among a group of international editors coming from the European Physical and Rehabilitation Medicine (PRM) Bodies supporting and co-authoring the ebook. A last check was then performed by the another PRM physician (FG), before the final decision by the European PRM Bodies took place. Results: To date, we have identified 375 CSRs published between 2014 and August 2019. Of these, 145 (3 for 2018, 68 for 2017, 60 for 2016 and 14 for 2015) have been assigned to and summarized by the residents. Ninety-six of them (45 for 2017, 48 for 2016 and 3 for 2015) have been finally approved and uploaded on the Ebook website. The remaining ones are undergoing one of the two processes of revision. Conclusions: The CR Ebook will be officially launched in the European Bodies Meeting, postponed from March to September 2020, and will be progressively filled with a new set of summaries completed and approved. The process started with the CSRs published in 2016 and 2017, and is now proceeding simultaneously onwards and backwards. The project is continuous: the number of CSRs to be summarized is meant to increase every time a CSR is tagged as relevant to rehabilitation, making the Ebook a “live” and updated source of evidence. CR is also planning to translate the summaries into different languages, as is already done for other KT products (i.e. blogshots), in order to reach the widest possible audience. Patient or healthcare consumer involvement: Patients or healthcare consumers have not been directly involved in the project, but represents one of the different audiences the Ebook addresses.

Published
2020

34. Neutrophil Extracellular Traps (NETs) profiles in patients with incident SLE and lupus nephritis

Author

Bruschi, M, Bonanni, A, Petretto, A, Vaglio, A, Pratesi, F, Santucci, L, Migliorini, P, Bertelli, R, Galetti, M, Belletti, S, Cavagna, L, Moroni, G, Franceschini, F, Fredi, M, Pazzola, G, Allegri, L, Sinico, Ra, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, Ga, Ramoino, P, Bianchini, P, Puppo, F, Pupo, F, Negrini, S, Mattana, F, Emmi, G, Garibotto, G, Santoro, D, Scolari, F, Ravelli, A, Tincani, A, Cravedi, P, Volpi, S, Candiano, G, Ghiggeri, Gm, Bruschi, M, Bonanni, A, Petretto, A, Vaglio, A, Pratesi, F, Santucci, L, Migliorini, P, Bertelli, R, Galetti, M, Belletti, S, Cavagna, L, Moroni, G, Franceschini, F, Fredi, M, Pazzola, G, Allegri, L, Sinico, R, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Ramoino, P, Bianchini, P, Puppo, F, Pupo, F, Negrini, S, Mattana, F, Emmi, G, Garibotto, G, Santoro, D, Scolari, F, Ravelli, A, Tincani, A, Cravedi, P, Volpi, S, Candiano, G, and Ghiggeri, G

Subjects
lupus nephritis, Systemic Lupus Erythematosus (SLE), Neutrophil Extracellular Traps (NETs)
Abstract

Objective. Neutrophil extracellular traps (NET) expose modified antigens for autoantibodies in vasculitis. Little is known about levels and removal pathways of NET in systemic lupus erythematosus (SLE), especially in lupus nephritis (LN). We determined circulating levels and defined NET removal in large subsets of patients with incident SLE (iSLE), some of whom had new-onset nephritis. Methods. Serum levels of NET (ELISA), DNase1/DNase1L3 (ELISA), and DNase activity (functional assay) were determined in 216 patients with iSLE [103 had incident LN (iLN)], in 50 patients with other primary glomerulonephritis, and in healthy controls. Ex vivo NET production by neutrophils purified from a random selection of patients was quantified as elastase/DNA release and by immunofluorescence techniques. Results. Serum NET levels were very high in iSLE/iLN compared to all groups of controls and correlated with anti-dsDNA, C3-C4, and proteinuria; iLN had the highest levels. DNase activity was decreased in iLN compared to SLE (20% had one-half DNase activity) despite similar serum levels of DNase1/DNase1L3. In these cases, pretreatment of serum with protein A restored DNase efficiency; 1 patient was homozygous for a c.289_290delAC variant of DNASE1L3. Ex vivo NET production by neutrophils purified from LN, SLE, and normal controls was similar in all cases. Conclusion. Patients with iLN have increased circulating NET and reduced DNase activity, the latter being explained by the presence of inhibitory substances in circulation and/or by rare DNase1L3 mutations. Accumulation of NET derives from a multifactorial mechanism, and is associated and may contribute to disease severity in SLE, in particular to renal lesions. (Clinical trial registration: The Zeus study was registered at ClinicalTrials.gov, study number NCT02403115).

Published
2020

35. Covid-19 and the role of smoking. The protocol of the multicentric prospective study COSMO-IT (COvid19 and SMOking in ITaly)

Author

Cattaruzza, M. S., Gorini, G., Bosetti, C., Boffi, R., Lugo, A., Veronese, C., Carreras, G., Santucci, C., Stival, C., Pacifici, R., Zaga, V., Gallus, S., Giulietti, F., Sarzani, R., Spannella, F., Del Donno, M., Tartaglione, S., Marrazzo, G., Pelaia, G., D'Agosto, V., Berti, A., Voller, F., Cardellicchio, S., Cresci, C., Foschino Barbaro, M. P., De Palma, R., Negrini, S., Sicbaldi, V., Serafini, A., Bisconti, M., Refolo, L., Landoni, G., Rovere, P., Veronesi, G., Faverio, P., Garavello, W., Pesci, A., Giacobbe, R., Martucci, P., Parrella, R., Scarano, F., Aiello, M., Chetta, A., Franco, C., Mangia, A., Carrozzi, L., Maggi, F., Monzani, F., Pistelli, F., Russo, P., Sanna, A., Barreca, F. M., Conti, V., Rossi, E., Ruli, M., Ruli, S., Varzaneh, S. E., Principe, R., Guerrini, S., Sebastiani, A., Galluccio, G., Pezzuto, A., Ricci, A., Casali, E., Mastroianni, C., Pirina, P., Polo, F., Beatrice, F., Romagnoli, M., Baraldo, M., Cojutti, P. G., Graziano, E., Pecori, D., Tascini, C., Tinghino, B., Cattaruzza, Maria Sofia, Gorini, Giuseppe, Bosetti, Cristina, Boffi, Roberto, Lugo, Alessandra, Veronese, Chiara, Carreras, Giulia, Santucci, Claudia, Stival, Chiara, Pacifici, Roberta, Zagà, Vincenzo, Gallus, Silvano, Giulietti, Federico, Sarzani, Riccardo, Spannella, Francesco, Del Donno, Mario, Tartaglione, Stefania, Marrazzo, Giuseppina, Pelaia, Girolamo, D'Agosto, Vincenzo, Berti, Alice, Voller, Fabio, Cardellicchio, Salvatore, Cresci, Chiara, Foschino Barbaro, Maria Pia, De Palma, Raffaele, Negrini, Simone, Sicbaldi, Vera, Serafini, Antonella, Bisconti, Mario, Refolo, Leonida, Landoni, Giovanni, Rovere, Patrizia, Veronesi, Giulia, Faverio, Paola, Garavello, Werner, Pesci, Alberto, Giacobbe, Raffaella, Martucci, Paola, Parrella, Roberto, Scarano, Francesco, Aiello, Marina, Chetta, Alfredo, Franco, Cosimo, Mangia, Angelo, Carrozzi, Laura, Maggi, Fabrizio, Monzani, Fabio, Pistelli, Francesco, Russo, Patrizia, Sanna, Antonio, Barreca, Filippo Maria, Conti, Valentina, Rossi, Enrico, Ruli, Mei, Ruli, Silvana, Eslami Varzaneh, Shokoofe, Principe, Rosastella, Guerrini, Simone, Sebastiani, Alfredo, Galluccio, Giovanni, Pezzuto, Aldo, Ricci, Alberto, Casali, Elena, Mastroianni, Claudio, Pirina, Pietro, Polo, Francesca, Beatrice, Fabio, Romagnoli, Micaela, Baraldo, Massimo, Cojutti, Pier Giorgio, Tascini, Carlo, Pecori, Davide, Graziano, Elena, Tinghino, Biagio, Cattaruzza, M, Gorini, G, Bosetti, C, Boffi, R, Lugo, A, Veronese, C, Carreras, G, Santucci, C, Stival, C, Pacifici, R, Zaga, V, Gallus, S, Giulietti, F, Sarzani, R, Spannella, F, Del Donno, M, Tartaglione, S, Marrazzo, G, Pelaia, G, D'Agosto, V, Berti, A, Voller, F, Cardellicchio, S, Cresci, C, Foschino Barbaro, M, De Palma, R, Negrini, S, Sicbaldi, V, Serafini, A, Bisconti, M, Refolo, L, Landoni, G, Rovere, P, Veronesi, G, Faverio, P, Garavello, W, Pesci, A, Giacobbe, R, Martucci, P, Parrella, R, Scarano, F, Aiello, M, Chetta, A, Franco, C, Mangia, A, Carrozzi, L, Maggi Monzani, F, Pistelli, F, Russo, P, Sanna, A, Barreca, F, Conti, V, Rossi, E, Ruli, M, Ruli, S, Varzaneh, S, Principe, R, Guerrini, S, Sebastiani, A, Galluccio, G, Pezzuto, A, Ricci, A, Casali, E, Mastroianni, C, Pirina, P, Polo, F, Beatrice, F, Romagnoli, M, Baraldo, M, Cojutti, P, Graziano, E, Pecori, D, Tascini, C, and Tinghino, B

Subjects
Male, Prognosi, Pneumonia, Viral, Lifestyle habit, COVID-19, Lifestyle habits, Prognosis, Risk factors, SARS-COV-2, Smoking, Tobacco, tobacco, smoking, Follow-Up Studie, Betacoronavirus, lifstyle habits, prognosis, tobacco, risk factors, Prevalence, Tobacco Smoking, Humans, risk factors, Viral, Prospective Studies, Life Style, Pandemics, lifestyle habits, Betacoronaviru, Pandemic, Coronavirus Infection, SARS-CoV-2, Pneumonia, Coronavirus Infections, Female, Follow-Up Studies, Italy, covid-19, sars-cov-2, Original Investigations / Commentaries, Prospective Studie, Risk factor, Human
Abstract

The emergency caused by Covid-19 pandemic raised interest in studying lifestyles and comorbidities as important determinants of poor Covid-19 prognosis. Data on tobacco smoking, alcohol consumption and obesity are still limited, while no data are available on the role of e-cigarettes and heated tobacco products (HTP). To clarify the role of tobacco smoking and other lifestyle habits on COVID-19 severity and progression, we designed a longitudinal observational study titled COvid19 and SMOking in ITaly (COSMO-IT). About 30 Italian hospitals in North, Centre and South of Italy joined the study. Its main aims are: 1) to quantify the role of tobacco smoking and smoking cessation on the severity and progression of COVID-19 in hospitalized patients; 2) to compare smoking prevalence and severity of the disease in relation to smoking in hospitalized COVID-19 patients versus patients treated at home; 3) to quantify the association between other lifestyle factors, such as e-cigarette and HTP use, alcohol and obesity and the risk of unfavourable COVID-19 outcomes. Socio-demographic, lifestyle and medical history information will be gathered for around 3000 hospitalized and 700-1000 home-isolated, laboratory-confirmed, COVID-19 patients. Given the current absence of a vaccine against SARS-COV-2 and the lack of a specific treatment for -COVID-19, prevention strategies are of extreme importance. This project, designed to highly contribute to the international scientific debate on the role of avoidable lifestyle habits on COVID-19 severity, will provide valuable epidemiological data in order to support important recommendations to prevent COVID-19 incidence, progression and mortality.

Published
2020

36. Impact of COVID-19 outbreak on rehabilitation services and Physical and Rehabilitation Medicine physicians' activities in Italy An official document of the Italian PRM Society (SIMFER)

Author

Boldrini P., Bernetti A., Fiore P., Bargellesi S., Bonaiuti D., Brianti R., Calvaruso S., Checchia G. A., Costa M., Galeri S., Lombardi B., Zambuto A., Capodaglio P., Ceravolo M. G., Ferriero G., Foti C., Franchignoni F., Gimigliano F., Giustini A., Kiekens C., Negrini S., Pestelli G., Zampolini M., Boldrini, P., Bernetti, A., Fiore, P., Bargellesi, S., Bonaiuti, D., Brianti, R., Calvaruso, S., Checchia, G. A., Costa, M., Galeri, S., Lombardi, B., Zambuto, A., Capodaglio, P., Ceravolo, M. G., Ferriero, G., Foti, C., Franchignoni, F., Gimigliano, F., Giustini, A., Kiekens, C., Negrini, S., Pestelli, G., and Zampolini, M.

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Pneumonia, Viral, MEDLINE, Physical Therapy, Sports Therapy and Rehabilitation, Health Services Accessibility, Settore MED/34, Betacoronavirus, Pandemic, medicine, Humans, Viral, Pandemics, Rehabilitation, biology, Coronavirus Infection, Viral Epidemiology, business.industry, SARS-CoV-2, Outbreak, COVID-19, Covid19, Pneumonia, rehabilitationi, biology.organism_classification, medicine.disease, Physical and Rehabilitation Medicine, Italy, Family medicine, physical and rehabilitation medicine, Coronavirus Infections, business, Human
Published
2020

37. Cognitive reserve as a useful variable to address robotic or conventional upper limb rehabilitation treatment after stroke: a multicentre study of the Fondazione Don Carlo Gnocchi

Author

Padua, L., Imbimbo, I., Aprile, I., Loreti, C., Germanotta, M., Coraci, D., Piccinini, G., Pazzaglia, C., Santilli, C., Cruciani, A., Carrozza, M. C., Pecchioli, C., Loreti, S., Lattanzi, S., Cortellini, L., Papadopoulou, D., Liberti, G., Panzera, F., Mitrione, P., Ruzzi, D., Rinaldi, G., Insalaco, S., De Santis, F., Spinelli, P., Marsan, S., Bastoni, I., Pellegrino, A., Petitti, T., Montesano, A., Castagna, A., Grosso, C., Ammenti, P., Cattaneo, D., Azzinnaro, L., Barbieri, D., Cassani, S., Corrini, C., Meotti, M., Parelli, R., Spedicato, A., Zocchi, M., Loffi, M., Manenti, D., Negri, L., Gramatica, F., Gower, V., Galeri, S., Noro, F., Medici, L., Garattini, R., Bariselli, F., Luli, M., Ricca, M., Negrini, S., Diverio, M., Giannini, E., Gabrielli, A., Deidda, B., Gnetti, B., Beatini, P., Callegari, S., Cabano, B., Converti, F., Pizzi, A., Falsini, C., Romanelli, A., De Luca, G., Vannetti, F., Simoncini, E., Martini, M., Peccini, E., Cecchi, F., Avila, L., Gabrielli, M. A., Barilli, M., Bertocchi, E., Giannarelli, G., Lerda, E., Vasoli, M., Rossi, P., Marsili, V., Tognoli, B., Bertolini, A., Vastola, G., Speranza, G., Colella, M., Mosca, R., Competiello, G., Chiusano, A., Della Vecchia, A., Soriano, P., Pagliarulo, M., Remollino, V., Langone, E., Santarsiero, R., Magliulo, M., Araneo, G., Galantucci, L., Lioi, N., Marrazzo, F., Larocca, S., Calia, R., Benevento, S., Toscano, O., and Lategana, M.

Subjects
medicine.medical_specialty, Barthel index, medicine.medical_treatment, Cognitive Reserve Index, rehabilitation, Upper Extremity, 03 medical and health sciences, 0302 clinical medicine, Cognitive Reserve, Robotic Surgical Procedures, medicine, Humans, 030212 general & internal medicine, Stroke, Cognitive reserve, robotics, Rehabilitation, business.industry, personalized medicine, stroke, Stroke Rehabilitation, Cognition, Recovery of Function, medicine.disease, Settore MED/26 - NEUROLOGIA, Treatment Outcome, Neurology, Physical therapy, Neurology (clinical), Stroke recovery, Upper limb rehabilitation, business, 030217 neurology & neurosurgery, Settore MED/34 - MEDICINA FISICA E RIABILITATIVA
Abstract

Background and purpose Rehabilitation plays a central role in stroke recovery. Besides conventional therapy, technological treatments have become available. The effectiveness and appropriateness of technological rehabilitation are not yet well defined; hence, research focused on different variables impacting recovery is needed. Results from the literature identified cognitive reserve (CR) as a variable impacting on the cognitive outcome. In this paper, the aim was to evaluate whether CR influences the motor outcome in patients after stroke treated with conventional or robotic therapy and whether it may influence one treatment rather than another. Methods Seventy-five stroke patients were enrolled in five Italian neurological rehabilitation centres. Patients were assigned either to a robotic group, rehabilitation by means of robotic devices, or to a conventional group, where a traditional approach was used. Patients were evaluated at baseline and after rehabilitation treatment of 6 weeks through the Action Research Arm Test (ARAT), the Motricity Index (MI) and the Barthel Index (BI). CR was assessed at baseline using the Cognitive Reserve Index (CRI) questionnaire. Results Considering all patients, a weak correlation was found between the CRI related to leisure time and MI evolution (r = 0.276; P = 0.02). Amongst the patients who performed a robotic rehabilitation, a moderate correlation emerged between the CRI related to working activities and MI evolution (r = 0.422; P = 0.02). Conclusions Our results suggest that CR may influence the motor outcome. For each patient, CR and its subcategories should be considered in the choice between conventional and robotic treatment.

Published
2019

40. Up to 2.2 million people experiencing disability suffer collateral damage each day of COVID-19 lockdown in Europe

Author

Negrini S, Grabljevec K, Boldrini P, Kiekens C, Moslavac S, Zampolini M, and Christodoulou N

Abstract

Background:The COVID-19 pandemic is having a great impact on health services. Patients not receiving care due to closure of outpatient services suffer a collateral damage. Our aim was to provide first data on impact of COVID-19 on people experiencing disability in Europe. Methods:We developed an estimation from a survey and publicly available data. Thirty-eight countries have been inquired through the European Bodies of Physical and Rehabilitation Medicine - the rehabilitation medical specialty. The nine questions of the survey focused on March 31st, 2020. We used the following indicators: for inpatients, acute and rehabilitative hospital beds; for outpatients, missing uniform European data, we used information from Italy, Belgium and the UK, and estimated for Europe basing on population, number of rehabilitation physicians, physiotherapists, and people with self-reported limitations. Results:Thirty-five countries (92%) including 99% of the population (809.9 million) answered. Stop of admissions to rehabilitation, early discharge and reduction of activities involved 194,800 inpatients in 10 countries. Outpatient activities stopped for 87%, involving 318,000 patients per day in Italy, Belgium and the UK, leading to an estimate range of 1.3-2.2 million in Europe. Seven countries reported experiences on rehabilitation for acute COVID-19 patients. Conclusions:COVID-19 emergency is having a huge impact on rehabilitation of people experiencing disability. This may lead to future cumulative effects due to reduced functional outcome and consequent increased burden of care. When the emergency will fade, rehabilitation demand will probably grow due to an expected return wave of these not well treated patients, but probably also of post-COVID-19 patients' needs.

Published
2021
Full Text
View/download PDF

42. Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY)

Author

Tubin, S, Gupta, S, Grusch, M, Popper, HH, Brcic, L, Ashdown, ML, Khleif, SN, Peter-Vorosmarty, B, Hyden, M, Negrini, S, Fossati, P, Hug, E, Tubin, S, Gupta, S, Grusch, M, Popper, HH, Brcic, L, Ashdown, ML, Khleif, SN, Peter-Vorosmarty, B, Hyden, M, Negrini, S, Fossati, P, and Hug, E

Abstract

Radiation-induced immune-mediated abscopal effects (AE) of conventional radiotherapy are very rare. Whole-tumor irradiation leads to lymphopenia due to killing of immune cells in the tumor microenvironment, resulting in immunosuppression and weak abscopal potential. This limitation may be overcome by partial tumor irradiation sparing the peritumoral immune-environment, and consequent shifting of immune-suppressive to immune-stimulatory effect. This would improve the radiation-directed tumor cell killing, adding to it a component of immune-mediated killing. Our preclinical findings showed that the high-single-dose irradiation of hypoxic tumor cells generates a stronger bystander effect (BE) and AE than the normoxic cells, suggesting their higher "immunogenic potential". This led to the development of a novel Stereotactic Body RadioTherapy (SBRT)-based PArtial Tumor irradiation targeting HYpoxic segment (SBRT-PATHY) for induction of the immune-mediated BE and AE. Encouraging SBRT-PATHY-clinical outcomes, together with immunohistochemical and gene-expression analyses of surgically removed abscopal-tumor sites, suggested that delivery of the high-dose radiation to the partial (hypoxic) tumor volume, with optimal timing based on the homeostatic fluctuation of the immune response and sparing the peritumoral immune-environment, would significantly enhance the immune-mediated anti-tumor effects. This review discusses the current evidence on the safety and efficacy of SBRT-PATHY in the treatment of unresectable hypoxic bulky tumors and its bystander and abscopal immunomodulatory potential.

Published
2021

43. Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study

Author

Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, D'Alessandro, M, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe A, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, d'Alessandro, Matteo, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, Ghiggeri, Gian Marco, Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, D'Alessandro, M, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe A, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, d'Alessandro, Matteo, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, and Ghiggeri, Gian Marco

Abstract

Objectives: Circulating anti-ENO1 and anti-H2A IgG2 have been identified as specific signatures of LN in a cross-over approach. We sought to show whether the same antibodies identify selected population of patients with LN with potentially different clinical outcomes. Methods: Here we report the prospective analysis over 36 months of circulating IgG2 levels in patients with newly diagnosed LN (n=91) and SLE (n=31) and in other patients with SLE recruited within 2 years from diagnosis (n=99). Anti-podocyte (ENO1), anti-nucleosome (DNA, histone 2 A, histone 3) and anti-circulating proteins (C1q, AnnexinA1-ANXA1) IgG2 antibodies were determined by home-made techniques. Results: LN patients were the main focus of the study. Anti-ENO1, anti-H2A and anti-ANXA1 IgG2 decreased in parallel to proteinuria and normalized within 12 months in the majority of patients while anti-dsDNA IgG2 remained high over the 36 months. Anti-ENO1 and anti-H2A had the highest association with proteinuria (Heat Map) and identified the highest number of patients with high proteinuria (68% and 71% respectively) and/or with reduced estimated glomerula filtration rate (eGFR) (58% for both antibodies) compared with 23% and 17% of anti-dsDNA (agreement analysis). Anti-ENO1 positive LN patients had higher proteinuria than negative patients at T0 and presented the maximal decrement within 12 months. Conclusions: Anti-ENO1, anti-H2A and anti-ANXA1 antibodies were associated with high proteinuria in LN patients and Anti-ENO1 also presented the maximal reduction within 12 months that paralleled the decrease of proteinuria. Anti-dsDNA were not associated with renal outcome parameters. New IgG2 antibody signatures should be utilized as tracers of personalized therapies in LN. Trial registration: The Zeus study was registered at https://clinicaltrials.gov (study number: NCT02403115).

Published
2021

44. Second wave antibodies in autoimmune renal diseases: The case of lupus nephritis

Author

Angeletti, A, Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, D'Alessandro, M, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Ravelli, A, Ghiggeri, G, Angeletti, Andrea, Bruschi, Maurizio, Moroni, Gabriela, Sinico, Renato, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, d'Alessandro, Matteo, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Ravelli, Angelo, Ghiggeri, Gian Marco, Angeletti, A, Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, D'Alessandro, M, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Ravelli, A, Ghiggeri, G, Angeletti, Andrea, Bruschi, Maurizio, Moroni, Gabriela, Sinico, Renato, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, d'Alessandro, Matteo, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Ravelli, Angelo, and Ghiggeri, Gian Marco

Abstract

Clinical Trial registry name and registration number: Zeus study, NCT02403115

Published
2021

45. Neutrophil Extracellular Traps in the Autoimmunity Context

Author

Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Manfredi, A, Ramirez, G, Esposito, P, Negrini, S, Trezzi, B, Emmi, G, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Manfredi, Angelo, Ramirez, Giuseppe A., Esposito, Pasquale, Negrini, Simone, Trezzi, Barbara, Emmi, Giacomo, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, Ghiggeri, Gian Marco, Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Manfredi, A, Ramirez, G, Esposito, P, Negrini, S, Trezzi, B, Emmi, G, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Manfredi, Angelo, Ramirez, Giuseppe A., Esposito, Pasquale, Negrini, Simone, Trezzi, Barbara, Emmi, Giacomo, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, and Ghiggeri, Gian Marco

Abstract

The formation of neutrophil extracellular traps (NETs) is a strategy utilized by neutrophils for capturing infective agents. Extracellular traps consist in a physical net made of DNA and intracellular proteins externalized from neutrophils, where bacteria and viruses are entrapped and killed by proteolysis. A complex series of events contributes to achieving NET formation: signaling from infectious triggers comes first, followed by decondensation of chromatin and extrusion of the nucleosome components (DNA, histones) from the nucleus and, after cell membrane breakdown, outside the cell. NETs are composed of either DNA or nucleosome proteins and hundreds of cytoplasm proteins, a part of which undergo post-translational modification during the steps leading to NETs. There is a thin balance between the production and the removal of circulating NETs from blood where digestion of DNA by circulating DNases 1 and IL3 has a critical role. A delay in NET removal may have consequences for autoimmunity. Recent studies have shown that circulating NET levels are increased in systemic lupus erythematosus (SLE) for a functional block of NET removal mediated by anti-DNase antibodies or, in rare cases, by DNase IL3 mutations. In SLE, the persistence in circulation of NETs signifies elevated concentrations of either free DNA/nucleosome components and oxidized proteins that, in some cases, are recognized as non-self and presented to B-cells by Toll-like receptor 9 (TLR9). In this way, it is activated as an immunologic response, leading to the formation of IgG2 auto-antibody. Monitoring serum NET levels represents a potential new way to herald the development of renal lesions and has clinical implications. Modulating the balance between NET formation and removal is one of the objectives of basic research that are aimed to design new drugs for SLE. Clinical Trial Registration Number: The Zeus study was registered at https://clinicaltrials.gov (study number: NCT02403115).

Published
2021

46. Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome)

Author

Bettiol, A, Sinico, R, Schiavon, F, Monti, S, Bozzolo, E, Franceschini, F, Govoni, M, Lunardi, C, Guida, G, Lopalco, G, Paolazzi, G, Vacca, A, Gregorini, G, Leccese, P, Piga, M, Conti, F, Fraticelli, P, Quartuccio, L, Alberici, F, Salvarani, C, Bettio, S, Negrini, S, Selmi, C, Sciascia, S, Moroni, G, Colla, L, Manno, C, Urban, M, Vannacci, A, Pozzi, M, Fabbrini, P, Polti, S, Felicetti, M, Marchi, M, Padoan, R, Delvino, P, Caporali, R, Montecucco, C, Dagna, L, Cariddi, A, Toniati, P, Tamanini, S, Furini, F, Bortoluzzi, A, Tinazzi, E, Delfino, L, Badiu, I, Rolla, G, Venerito, V, Iannone, F, Berti, A, Bortolotti, R, Racanelli, V, Jeannin, G, Padula, A, Cauli, A, Priori, R, Gabrielli, A, Bond, M, Tedesco, M, Pazzola, G, Tomietto, P, Pellecchio, M, Marvisi, C, Maritati, F, Palmisano, A, Dejaco, C, Willeit, J, Kiechl, S, Olivotto, I, Willeit, P, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Sinico, Renato Alberto, Schiavon, Franco, Monti, Sara, Bozzolo, Enrica Paola, Franceschini, Franco, Govoni, Marcello, Lunardi, Claudio, Guida, Giuseppe, Lopalco, Giuseppe, Paolazzi, Giuseppe, Vacca, Angelo, Gregorini, Gina, Leccese, Pietro, Piga, Matteo, Conti, Fabrizio, Fraticelli, Paolo, Quartuccio, Luca, Alberici, Federico, Salvarani, Carlo, Bettio, Silvano, Negrini, Simone, Selmi, Carlo, Sciascia, Savino, Moroni, Gabriella, Colla, Loredana, Manno, Carlo, Urban, Maria Letizia, Vannacci, Alfredo, Pozzi, Maria Rosa, Fabbrini, Paolo, Polti, Stefano, Felicetti, Mara, Marchi, Maria Rita, Padoan, Roberto, Delvino, Paolo, Caporali, Roberto, Montecucco, Carlomaurizio, Dagna, Lorenzo, Cariddi, Adriana, Toniati, Paola, Tamanini, Silvia, Furini, Federica, Bortoluzzi, Alessandra, Tinazzi, Elisa, Delfino, Lorenzo, Badiu, Iuliana, Rolla, Giovanni, Venerito, Vincenzo, Iannone, Florenzo, Berti, Alvise, Bortolotti, Roberto, Racanelli, Vito, Jeannin, Guido, Padula, Angela, Cauli, Alberto, Priori, Roberta, Gabrielli, Armando, Bond, Milena, Tedesco, Martina, Pazzola, Giulia, Tomietto, Paola, Pellecchio, Marco, Marvisi, Chiara, Maritati, Federica, Palmisano, Alessandra, Dejaco, Christian, Willeit, Johann, Kiechl, Stefan, Olivotto, Iacopo, Willeit, Peter, Prisco, Domenico, Vaglio, Augusto, Emmi, Giacomo, Bettiol, A, Sinico, R, Schiavon, F, Monti, S, Bozzolo, E, Franceschini, F, Govoni, M, Lunardi, C, Guida, G, Lopalco, G, Paolazzi, G, Vacca, A, Gregorini, G, Leccese, P, Piga, M, Conti, F, Fraticelli, P, Quartuccio, L, Alberici, F, Salvarani, C, Bettio, S, Negrini, S, Selmi, C, Sciascia, S, Moroni, G, Colla, L, Manno, C, Urban, M, Vannacci, A, Pozzi, M, Fabbrini, P, Polti, S, Felicetti, M, Marchi, M, Padoan, R, Delvino, P, Caporali, R, Montecucco, C, Dagna, L, Cariddi, A, Toniati, P, Tamanini, S, Furini, F, Bortoluzzi, A, Tinazzi, E, Delfino, L, Badiu, I, Rolla, G, Venerito, V, Iannone, F, Berti, A, Bortolotti, R, Racanelli, V, Jeannin, G, Padula, A, Cauli, A, Priori, R, Gabrielli, A, Bond, M, Tedesco, M, Pazzola, G, Tomietto, P, Pellecchio, M, Marvisi, C, Maritati, F, Palmisano, A, Dejaco, C, Willeit, J, Kiechl, S, Olivotto, I, Willeit, P, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Sinico, Renato Alberto, Schiavon, Franco, Monti, Sara, Bozzolo, Enrica Paola, Franceschini, Franco, Govoni, Marcello, Lunardi, Claudio, Guida, Giuseppe, Lopalco, Giuseppe, Paolazzi, Giuseppe, Vacca, Angelo, Gregorini, Gina, Leccese, Pietro, Piga, Matteo, Conti, Fabrizio, Fraticelli, Paolo, Quartuccio, Luca, Alberici, Federico, Salvarani, Carlo, Bettio, Silvano, Negrini, Simone, Selmi, Carlo, Sciascia, Savino, Moroni, Gabriella, Colla, Loredana, Manno, Carlo, Urban, Maria Letizia, Vannacci, Alfredo, Pozzi, Maria Rosa, Fabbrini, Paolo, Polti, Stefano, Felicetti, Mara, Marchi, Maria Rita, Padoan, Roberto, Delvino, Paolo, Caporali, Roberto, Montecucco, Carlomaurizio, Dagna, Lorenzo, Cariddi, Adriana, Toniati, Paola, Tamanini, Silvia, Furini, Federica, Bortoluzzi, Alessandra, Tinazzi, Elisa, Delfino, Lorenzo, Badiu, Iuliana, Rolla, Giovanni, Venerito, Vincenzo, Iannone, Florenzo, Berti, Alvise, Bortolotti, Roberto, Racanelli, Vito, Jeannin, Guido, Padula, Angela, Cauli, Alberto, Priori, Roberta, Gabrielli, Armando, Bond, Milena, Tedesco, Martina, Pazzola, Giulia, Tomietto, Paola, Pellecchio, Marco, Marvisi, Chiara, Maritati, Federica, Palmisano, Alessandra, Dejaco, Christian, Willeit, Johann, Kiechl, Stefan, Olivotto, Iacopo, Willeit, Peter, Prisco, Domenico, Vaglio, Augusto, and Emmi, Giacomo

Published
2021

47. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis

Author

Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Volpi, S, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela&nbsp, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello&nbsp, Manfredi, Angelo, Ramirez, Giuseppe A, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Mosca, Marta, Tincani, Angela&nbsp, Candiano, Giovanni, Prunotto, Marco, Volpi, Stefano, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, Ghiggeri, Gian Marco, Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Volpi, S, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela&nbsp, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello&nbsp, Manfredi, Angelo, Ramirez, Giuseppe A, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Mosca, Marta, Tincani, Angela&nbsp, Candiano, Giovanni, Prunotto, Marco, Volpi, Stefano, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, and Ghiggeri, Gian Marco

Abstract

Objectives: Serum anti-dsDNA and anti-nucleosome IgGs have been proposed as signatures for SLE and LN in limited numbers of patients. We sought to show higher sensitivity and specificity of the same antibodies with the IgG2 isotype and included IgG2 antibodies vs specific intracellular antigens in the analysis. Methods: A total of 1052 SLE patients with (n = 479) and without (n = 573) LN, recruited at different times from the beginning of symptoms, were included in the study. Patients with primary APS (PAPS, n = 24), RA (RA, n = 24) and UCTD (UCTD, n = 96) were analysed for comparison. Anti-nucleosome (dsDNA, Histone2A, Histone3), anti-intracellular antigens (ENO1), anti-annexin A1 and anti-C1q IgG2 were determined by non-commercial techniques. Results: The presence in the serum of the IgG2 panel was highly discriminatory for SLE/LN vs healthy subjects. Serum levels of anti-dsDNA and anti-C1q IgG2 were more sensitive than those of IgGs (Farr radioimmunoassay/commercial assays) in identifying SLE patients at low-medium increments. Of more importance, serum positivity for anti-ENO1 and anti-H2A IgG2 discriminated between LN and SLE (ROC T0-12 months), and high levels at T0-1 month were detected in 63% and 67%, respectively, of LN, vs 3% and 3%, respectively, of SLE patients; serum positivity for each of these was correlated with high SLEDAI values. Minor differences existed between LN/SLE and the other rheumatologic conditions. Conclusion: Nephritogenic IgG2 antibodies represent a specific signature of SLE/LN, with a few overlaps with other rheumatologic conditions. High levels of anti-ENO1 and anti-H2A IgG2 correlated with SLE activity indexes and were discriminatory between SLE patients limited to the renal complication and other SLE patients. Trial registration: The Zeus study was registered at https://clinicaltrials.gov, NCT02403115.

Published
2021

48. Neuropsychological features of severe hospitalized COVID-19 patients at clinical stability and clues for post-acute rehabilitation

Author

Negrini, F, Ferrario, I, Mazziotti, D, Berchicci, M, Bonazzi, M, de Sire, A, Negrini, S, Zapparoli, L, Negrini, Francesco, Ferrario, Irene, Mazziotti, Daniele, Berchicci, Marzia, Bonazzi, Maurizio, de Sire, Alessandro, Negrini, Stefano, Zapparoli, Laura, Negrini, F, Ferrario, I, Mazziotti, D, Berchicci, M, Bonazzi, M, de Sire, A, Negrini, S, Zapparoli, L, Negrini, Francesco, Ferrario, Irene, Mazziotti, Daniele, Berchicci, Marzia, Bonazzi, Maurizio, de Sire, Alessandro, Negrini, Stefano, and Zapparoli, Laura

Abstract

Objectives: To report the cognitive features of patients with severe coronavirus disease 2019 (COVID-19) entering the postacute phase, to understand whether COVID-19 acute respiratory distress syndrome itself could result in long-term cognitive deficits, and to determine whether neuropsychological treatment after the acute stage might represent a specific rehabilitation need. Design: Case series. Setting: Rehabilitation hospital. Participants: We assessed the general cognitive functioning through tablet-supported video calls in 9 of 12 consecutive patients (N=9) admitted to the hospital at least 30 days earlier for acute respiratory distress syndrome due to COVID-19. Three patients were excluded based on the exclusion criteria. None of the patients presented cognitive symptoms before hospitalization. Main Outcome Measure: General cognitive functioning, measured using the Mini-Mental State Examination (MMSE) test. Results: A general cognitive decay was observed in 3 patients (33.3%) who had a pathologic score on the MMSE, with a specific decline in attention, memory, language, and praxis abilities. The cognitive malfunctioning appears to be linearly associated with the length of stay (in d) in the intensive care unit (ICU). The longer the amount of time spent in the ICU, the lower the MMSE score, indicating a lower global cognitive functioning. Conclusions: Our results indicate that some patients with COVID-19 might also benefit from neuropsychological rehabilitation, given their possible global cognitive decay. The link between neuropsychological functioning and the length of stay in the ICU suggests that neurocognitive rehabilitative treatments should be directed explicitly toward patients who treated in the ICU, rather than toward every patient who experienced acute respiratory distress syndrome owing to COVID-19. However, given the limitation of a case series study, those hypotheses should be tested with future studies with larger samples and a longer follow-up p

Published
2021

50. Measurement of the longitudinal spin transfer to Λ and $\bar{\varLambda}$ hyperons in polarised muon DIS

Author

Alekseev, M., Alexakhin, V. Yu., Alexandrov, Yu., Alexeev, G. D., Amoroso, A., Austregesilo, A., Badełek, B., Balestra, F., Ball, J., Barth, J., Baum, G., Bedfer, Y., Bernhard, J., Bertini, R., Bettinelli, M., Birsa, R., Bisplinghoff, J., Bordalo, P., Bradamante, F., Bravar, A., Bressan, A., Brona, G., Burtin, E., Bussa, M. P., Chapiro, A., Chiosso, M., Chung, S. U., Cicuttin, A., Colantoni, M., Crespo, M. L., Dalla Torre, S., Dafni, T., Das, S., Dasgupta, S. S., Denisov, O. Yu., Dhara, L., Diaz, V., Dinkelbach, A. M., Donskov, S. V., Doshita, N., Duic, V., Dünnweber, W., Efremov, A., Eversheim, P. D., Eyrich, W., Faessler, M., Ferrero, A., Finger, M., Finger, Jr., M., Fischer, H., Franco, C., Friedrich, J. M., Garfagnini, R., Gautheron, F., Gavrichtchouk, O. P., Gazda, R., Gerassimov, S., Geyer, R., Giorgi, M., Gobbo, B., Goertz, S., Grabmüller, S., Grajek, O. A., Grasso, A., Grube, B., Gushterski, R., Guskov, A., Haas, F., von Harrach, D., Hasegawa, T., Heckmann, J., Heinsius, F. H., Hermann, M., Hermann, R., Herrmann, F., Heß, C., Hinterberger, F., Horikawa, N., Höppner, Ch., d’Hose, N., Ilgner, C., Ishimoto, S., Ivanov, O., Ivanshin, Yu., Iven, B., Iwata, T., Jahn, R., Jasinski, P., Jegou, G., Joosten, R., Kabuß, E., Kang, D., Ketzer, B., Khaustov, G. V., Khokhlov, Yu. A., Kisselev, Yu., Klein, F., Klimaszewski, K., Koblitz, S., Koivuniemi, J. H., Kolosov, V. N., Komissarov, E. V., Kondo, K., Königsmann, K., Konopka, R., Konorov, I., Konstantinov, V. F., Korzenev, A., Kotzinian, A. M., Kouznetsov, O., Kowalik, K., Krämer, M., Kral, A., Kroumchtein, Z. V., Kuhn, R., Kunne, F., Kurek, K., Le Goff, J. M., Lednev, A. A., Lehmann, A., Levorato, S., Lichtenstadt, J., Liska, T., Maggiora, A., Maggiora, M., Magnon, A., Mallot, G. K., Mann, A., Marchand, C., Marroncle, J., Martin, A., Marzec, J., Massmann, F., Matsuda, T., Maximov, A. N., Meyer, W., Michigami, T., Mikhailov, Yu. V., Moinester, M. A., Mutter, A., Nagaytsev, A., Nagel, T., Nassalski, J., Negrini, S., Nerling, F., Neubert, S., Neyret, D., Nikolaenko, V. I., Olshevsky, A. G., Ostrick, M., Padee, A., Panknin, R., Panzieri, D., Parsamyan, B., Paul, S., Pawlukiewicz-Kaminska, B., Perevalova, E., Pesaro, G., Peshekhonov, D. V., Piragino, G., Platchkov, S., Pochodzalla, J., Polak, J., Polyakov, V. A., Pontecorvo, G., Pretz, J., Quintans, C., Rajotte, J.-F., Ramos, S., Rapatsky, V., Reicherz, G., Reggiani, D., Richter, A., Robinet, F., Rocco, E., Rondio, E., Ryabchikov, D. I., Samoylenko, V. D., Sandacz, A., Santos, H., Sapozhnikov, M. G., Sarkar, S., Sbrizzai, G., Schiavon, P., Schill, C., Schmitt, L., Schröder, W., Shevchenko, O. Yu., Siebert, H.-W., Silva, L., Sinha, L., Sissakian, A. N., Slunecka, M., Smirnov, G. I., Sosio, S., Sozzi, F., Srnka, A., Stolarski, M., Sulc, M., Sulej, R., Takekawa, S., Tessaro, S., Tessarotto, F., Teufel, A., Tkatchev, L. G., Venugopal, G., Virius, M., Vlassov, N. V., Vossen, A., Weitzel, Q., Windmolders, R., Wiślicki, W., Wollny, H., Zaremba, K., Zemlyanichkina, E., Ziembicki, M., Zhao, J., Zhuravlev, N., and Zvyagin, A.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results